Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges?
Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges?
复制标题
DOI：
10.1016/j.hoc.2012.12.004
复制
发表时间：
2013-04-01
影响因子：
2.4
通讯作者：
Brentjens, Renier
中科院分区：
文献类型：
--
作者：
Davila, Marco L.;Brentjens, Renier
针对正常和恶性B细胞表达的CD19的嵌合抗原受体(CAR)修饰的T细胞是治疗慢性淋巴细胞白血病(CLL)的独特方法；最近的研究结果强调了这种治疗复发CLL的潜力。由于CAR修饰的T细胞过继转移是一种新的方法，因此在评估CLL患者当前和未来的临床试验时，内科肿瘤学家需要考虑一些问题。本文综述了CAR的设计、T细胞的产生、T细胞的剂量、调节方案以及CAR改良的T细胞输注时的肿瘤负荷对该治疗效果的影响。
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL. Because adoptive transfer of CAR-modified T cells is a novel approach, there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients. This article reviews the impact of CAR design, T-cell production, T-cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy.